APA (7th ed.) Citation

Braunstein, Z., Waller, A., Dotson, E., McLaughlin, E., Hanel, W., Reneau, J., . . . Brammer, J. E. (2024). Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas. Leukemia & Lymphoma, 65(3), 301. https://doi.org/10.1080/10428194.2023.2287965

Chicago Style (17th ed.) Citation

Braunstein, Zachary, Allyson Waller, Emily Dotson, Eric McLaughlin, Walter Hanel, John Reneau, Daniel Addison, Pierluigi Porcu, and Jonathan Edward Brammer. "Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-cell Lymphomas." Leukemia & Lymphoma 65, no. 3 (2024): 301. https://doi.org/10.1080/10428194.2023.2287965.

MLA (9th ed.) Citation

Braunstein, Zachary, et al. "Gemcitabine and Liposomal Doxorubicin (GemDox) for the Treatment of Relapsed and Refractory T-cell Lymphomas." Leukemia & Lymphoma, vol. 65, no. 3, 2024, p. 301, https://doi.org/10.1080/10428194.2023.2287965.